Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Arvinas Inc

ARVN
Current price
27.04 USD -0.62 USD (-2.24%)
Last closed 25.9 USD
ISIN US04335A1051
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 793 774 720 USD
Yield for 12 month +75.81 %
1Y
3Y
5Y
10Y
15Y
ARVN
21.11.2021 - 28.11.2021

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. Address: 5 Science Park, New Haven, CT, United States, 06511

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

65.78 USD

P/E ratio

Dividend Yield

Current Year

+78 500 000 USD

Last Year

+131 400 000 USD

Current Quarter

+76 500 000 USD

Last Quarter

+25 300 000 USD

Current Year

+71 800 000 USD

Last Year

+131 400 000 USD

Current Quarter

+74 800 000 USD

Last Quarter

+23 600 000 USD

Key Figures ARVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -366 200 000 USD
Operating Margin TTM -63.4 %
PE Ratio
Return On Assets TTM -19.63 %
PEG Ratio
Return On Equity TTM -60.8 %
Wall Street Target Price 65.78 USD
Revenue TTM 93 300 000 USD
Book Value 8.75 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 40.4 %
Dividend Yield
Gross Profit TTM 131 400 000 USD
Earnings per share -5.3 USD
Diluted Eps TTM -5.3 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ARVN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 17.6991
Enterprise Value Revenue 6.079
Price Sales TTM 19.2259
Enterprise Value EBITDA -1.6185
Price Book MRQ 2.9891

Financials ARVN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARVN

For 52 weeks

13.57 USD 53.08 USD
50 Day MA 25.09 USD
Shares Short Prior Month 12 756 198
200 Day MA 33.48 USD
Short Ratio 24.36
Shares Short 10 672 118
Short Percent 15.83 %